Cardiol Therapeutics Inc. Stock Price

TSX:CRDL Community·CA$139.4m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
13 Fair Values set on narratives written by author

Create a narrative

CRDL Share Price Performance

CA$1.37

-0.85 (-38.29%)

CA$1.37

-0.85 (-38.29%)

CA$1.37

Fri, 21 Nov 25

Share Pricen/a

CRDL Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Flawless balance sheet with moderate growth potential.

3 Risks

1 Reward

View Full Analysis

Cardiol Therapeutics Inc. Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

n/a

: -0.35
: 0%
: 0%
: 0%

View Full Analysis

About CRDL

Founded: 2017
Employees: 18
CEO: David Elsley
WebsiteView website: www.cardiolrx.com

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.